Abstract
Background In Mexico, some of the most prevalent non-communicable diseases (NCDs) among adults are diabetes, hypertension, and chronic kidney disease (CKD). Mexico could be going through a syndemic of dengue and NCDs. This study aims to describe and analyze the association between the prevalence of NCDs and hospitalization, the presence of hemorrhagic disorders, and death in all officially confirmed cases of dengue in Mexico during 2024.
Methodology/Principal Findings This cross-sectional study is carried out through a secondary analysis of the confirmed cases of dengue reported in 2024. The likelihood of hospitalization, hemorrhagic disorders, and death were assessed according to NCDs, estimating odds ratios (ORs). A multivariate logistic regression model was used, adjusting by age, sex, and for each of the NCDs (diabetes, hypertension, chronic kidney disease, immunosuppression, cirrhosis, and peptic ulcer disease). The most co-prevalent non-communicable diseases were diabetes, hypertension, CKD, and immunosuppression. For hospitalization, CKD has the highest risk of hospitalization (OR 5.73), followed by immunosuppression (OR 2.84), peptic ulcer disease (OR 2.35), and diabetes (OR 2.09). We found higher probabilities for having bleeding disorders in people with diabetes (OR 19.51), peptic ulcer disease (OR 7.85), immunosuppression (OR 4.75), cirrhosis (OR 3.37), and hypertension (OR 2.99) compared to people who did not have these diseases. The highest risk for death was observed in the cases with CKD (OR 6.54), followed by peptic ulcer disease (OR 3.09) and diabetes (OR 2.87).
Conclusions/Significance Patients with dengue and some comorbidities were more likely to have worse clinical outcomes, such as being hospitalized, having bleeding disorders, or dying. The syndemic of NCDs and dengue in Mexico has been rapidly increasing, and this problem needs to be addressed. This work demonstrates that patients with these comorbidities have worse clinical outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Expemption is granted because this is a study based on secondary data sources.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
https://www.gob.mx/cms/uploads/attachment/file/965318/Datos_abiertos_historicos_etv_2024.pdf
